PREP (Pre-Exposure Prophylaxis) of COVID-19

Ghady Haidar138 enrolled

Overview

This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies against SARS-CoV-2 (the virus that causes COVID-19), and other blood responses related to the immune system and COVID-19. Investigators are collecting blood and may also collect other samples such as nose swabs, oral swabs, or saliva.

This is a prospective study of 500 immunocompromised participants at UPMC health system. EVUSHELD will be given according to the EUA in the United States as a part of standard of care by the patient's health care provider. Patients who receive intramuscular EVUSHELD as standard of care will be enrolled and followed for 12-months. The target sample size is 500 immunocompromised individuals; serum concentrations of AZD7442 will be obtained in all patients at the 6 (or at enrollment if the time point has passed) and 12 month timepoints.

Study Type

OBSERVATIONAL

Enrollment

138

Conditions

Immuno-Deficiency COVID-19

Interventions

EvusheldDRUG

Participants who have received or plan to receive Evusheld.

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 12 and at least 40 kg * Eligible for EVUSHELD as per the EUA Exclusion Criteria: * Active and confirmed COVID-19 * Known or suspected pregnancy, concurrent lactation * Any other significant disease, disorder, or finding, in the opinion of the investigator, that may significantly increase the risk to the participant because of participation in the study, affect the ability of the subject to participate in the study, or impair interpretation of the study data

Locations (1)

UPMC

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS] Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS] Concentration of AZD7442 in serum over time [ENROLLMENT, 6 MONTHS, 12 MONTHS]

The primary objective of PrEP C-19 is to measure AZD7442 serum concentration levels by blood draws at 6 months (or at enrollment if the time point has passed) and 12 months after IM administration of EVUSHELD.

Time frame: 12-months

Secondary Outcomes

Concentration of AZD7442 in serum

Collected at 1, 3, AND 9 months

Time frame: 12-months

Assessment of SARS-CoV-2 Spike IgG levels using Bioplex/Biorad assays, viral neutralization assay using competitive ACE2 EIA, and pseudovirus neutralization titers

Collected at enrollment and 1, 3, 6, 9, and 12 months

Time frame: 12-months

Assessment of T-cell responses using an ELISPOT assay

Obtained before and after vaccination

Time frame: 12-months

Determining SARS_CoV-2 variant type using whole genome sequencing

Collected among subjects with breakthrough infection

Time frame: 12-months

Determining Concentration of AZD7442 in serum, SARS-CoV-2 Spike IgG levels using Bioplex/Biorad assays, viral neutralization assay using competitive ACE2 EIA, and pseudovirus neutralization titers

Collected during breakthrough infection

Time frame: 12-months

Proportion of participants with ≥1 COVID-19-related medically-attended visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.